AU Patent

AU2020213678A1 — PSMA binding dual mode radiotracer and therapeutic

Assigned to Technische Universitaet Muenchen · Expires 2021-08-12 · 5y expired

What this patent protects

The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally

USPTO Abstract

The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally

Drugs covered by this patent

Patent Metadata

Patent number
AU2020213678A1
Jurisdiction
AU
Classification
—
Expires
2021-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Technische Universitaet Muenchen
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.